(Q38180981)

30 August 2017

title

New therapeutic vaccination strategies for the treatment of chronic hepatitis B. (English)

1 reference

30 August 2017

1 reference

Jia Liu

1

1 reference

30 August 2017

Anna Kosinska

series ordinal

2

1 reference

30 August 2017

Mengji Lu

series ordinal

3

1 reference

30 August 2017

Michael Roggendorf

series ordinal

4

1 reference

30 August 2017

publication date

17 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

29

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

10-16

1 reference

https://scigraph.springernature.com/pub.10.1007/s12250-014-3410-5

30 August 2017

exact match

0 references

cites work

Restoring function in exhausted CD8 T cells during chronic viral infection

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

The molecular biology of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Pathogenesis of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

New insight in the pathobiology of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Hepatitis B: the virus and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Cellular and virological mechanisms of HBV drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Applications of pox virus vectors to vaccination: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Recombinant vaccinia virus: immunization against multiple pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

New hope for an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Adenoviruses as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Enhancing SIV-specific immunity in vivo by PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Blockade of Tim-3 signaling restores the virus-specific CD8⁺ T-cell response in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Immune effectors required for hepatitis B virus clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Hepatitis B virus resistance to nucleos(t)ide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3410-5

Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy

21 January 2018

1 reference

12 December 2020

A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy

1 reference

12 December 2020

Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers

1 reference

12 December 2020

Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients

1 reference

12 December 2020

Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection

1 reference

12 December 2020

Specific vaccine therapy in chronic hepatitis B infection

1 reference

12 December 2020

Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine

1 reference

12 December 2020

Specific Hepatitis B Vaccine Therapy in Inactive HBsAg Carriers: A Randomized Controlled Trial

1 reference

12 December 2020

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

12 December 2020

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

12 December 2020

10.1007/S12250-014-3410-5

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1013421828

0 references

1 reference